uniQure N.V. (QURE)

Between April 9, 2025, and April 8, 2026, the share price increased. The company experienced a market cap gain prior to September 1, 2025. A stock collapse occurred in November 2025 due to FDA concerns regarding AMT-130 data. QURE stock crashed around March 6, 2026, and lost value in the weeks surrounding March 4, 2026. Shares plummeted on March 2, 2026, after a mixed earnings report and the FDA's rejection of AMT-130 data for accelerated approval. Multiple securities fraud class action lawsuits have intensified investor concern. The company received analyst upgrades in March 2026. Other events include financial results announcements, regulatory updates, and data updates for Fabry Disease.

Traditional demand seasonality is not a significant factor for uniQure N.V. Demand for their products is primarily driven by disease prevalence, clinical trial progress, regulatory approvals, and physician adoption, rather than seasonal consumer patterns.

uniQure N.V. is a gene therapy company focused on developing and commercializing innovative gene therapies for genetic and other devastating diseases. They operate in the Healthcare sector, specifically in the Biotechnology & Drugs and Drug Discovery industries, developing one-time administered treatments with potentially curative results using AAV-based gene therapies produced in their own facilities. Their major products and pipeline programs include Hemgenix® (etranacogene dezaparvovec) for hemophilia B, AMT-130 for Huntington's disease, and other programs for cardiovascular diseases, Temporal Lobe Epilepsy (TLE), Fabry Disease, and ALS (SOD1).

uniQure N.V. is headquartered in Amsterdam, Netherlands, and plans to expand its global market presence in North America, Europe, and Asia.

uniQure's brand reputation has been negatively impacted by regulatory setbacks and legal challenges. An FDA official's comments and allegations of data manipulation contributed to a stock collapse and securities fraud class action lawsuits, creating negative sentiment and scrutiny around the company's programs and data integrity.

uniQure N.V.'s ownership is primarily institutional, with institutional investors holding a majority of the company's stock, followed by the general public and insiders. Major institutional shareholders include Fmr Llc, Avoro Capital Advisors LLC, RTW Investments, LP, Standard Life Aberdeen plc, State Street Corp, Jpmorgan Chase & Co, Susquehanna International Group, Llp, BlackRock, Inc., Two Sigma Investments, Lp, and MPM Oncology Impact Management LP. The company's CEO, Matthew Kapusta, directly holds a portion of the total shares outstanding.